GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

HTG Molecular Diagnostics HTGMQ · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

HTG Molecular Diagnostics — daily HTGMQ Delayed
Market value
$221
Last close × shares
Volume
125
Shares, 30 Oct 2026

About HTG Molecular Diagnostics

Its shares trade under the ticker HTGMQ. It has been listed since 6 May 2015. In the fiscal year to 31 December 2022, it reported revenue of $6.4m and a net loss of $21.6m. At that date it held total assets of $17.8m and shareholders' equity of $5.4m.

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. The company is headquartered in Tucson, Arizona. The company went IPO on 2015-05-06. The firm is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The firm is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and from sample processing services. Its HTG EdgeSeq profiling technology measures ribonucleic acid (RNA) using deoxyribonucleic acid (DNA) nuclease protection probes (DNA protection probes). Its profiling product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Its menu of HTG EdgeSeq assays includes the HTG Transcriptome Panel (HTP), which is designed to measure approximately 20,000 mRNA targets using its HTG EdgeSeq technology, is automated on its HTG EdgeSeq system.

Figures and description from our data supplier, not checked against the company's own report.

More about HTG Molecular Diagnostics →

Latest on HTG Molecular Diagnostics

Our reporting

We have not reported on HTG Molecular Diagnostics yet.

Next results

13 Nov 2026

Due on 13 Nov 2026. Analysts expect earnings of -11.80 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is HTG Molecular Diagnostics's ticker?

HTG Molecular Diagnostics trades as HTGMQ on its US listing, under ISIN US40434H3021.

What was HTG Molecular Diagnostics's last closing price?

0.00 on 30 Oct 2026. The figure is in USD and is never converted.

When does HTG Molecular Diagnostics next report results?

Results are expected on 13 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.